Literature DB >> 1586590

Sequential alteration of peanut agglutinin binding-glycoprotein expression during progression of murine mammary neoplasia.

J W Rak1, D McEachern, F R Miller.   

Abstract

A sequential, quantitative loss of Peanut agglutinin (PNA) binding with progression of mouse mammary cells from normal to preneoplastic to neoplastic phenotypes was observed. Normal mammary epithelium, preneoplastic mammary lesions designated D2HAN (D2-type hyperplastic alveolar nodules) and a series of nine spontaneous tumours (D2ST1, D2ST2, D2ST3, D2ST4, D2A1, D2F2, D2.0R, D2.1, EMT6R08) derived from mice bearing D2HAN were grown in culture and analysed by flow cytometry with respect to PNA binding intensity to the cell surface. Primary cultures of normal mammary epithelium strongly bound PNA. A stepwise decrease in PNA binding by preneoplastic D2HAN cells and subsequent tumours arising from those hyperplastic lesions was observed. Three cloned tumour subpopulations derived from such tumours exhibited dramatic differences in PNA binding ranging from high (D2.0R) to low (D2.1) to very low (D2A1 cells). Their growth rate in vitro was similar. However, an inverse correlation between PNA binding and malignant characteristics, such as the incidence and latency of subcutaneous tumours and the efficiency of the tumour cells to form lung colonies after i.v. injection, existed. Cells subsequently derived from tumours resulting from injection of the D2.0R clone (high PNA binding, low tumorigenicity) were found to have diminished PNA binding properties and to be more tumorigenic when reimplanted into syngeneic mice. The difference in PNA binding (up to 50-fold) between normal mammary cells and other mouse mammary tumour cells, i.e., unrelated to D2HAN lesions, was also seen. These include six sister subpopulations derived from a single BALB/cfC3H mouse mammary tumour (lines: 67, 66c14, 168FARN, 4TO7, 68H, 64pT) as well as SP1 spontaneous CBA/J mouse mammary carcinoma. The difference was greatly reduced by neuraminidase treatment suggesting a masking of PNA binding sites by sialic acid. Separation of cell lysates by SDS-PAGE revealed a high molecular weight PNA binding glycoprotein (greater than 250 kd) expressed by normal mammary epithelium and preneoplastic D2HAN cells, but not by tumour cells regardless of neuraminidase treatment. A PNA reactive glycoprotein of approximately 90 kd was uniquely expressed in normal mammary epithelial lysates, although neuraminidase treatment exposed a similar band in a few tumour lines. Normal mammary epithelium, preneoplastic D2HAN cells, and the poorly tumorigenic clone D2.0R expressed a PNA binding glycoprotein of approximately 150 kd. This band appeared to be specifically sialylated during transition from the high PNA binding, low tumorigenic phenotype of D2.0R cells to the low PNA binding, highly tumorigenic phenotype of cells isolated from tumours resulting from s.c. implantation of D2.0R cells.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1586590      PMCID: PMC1977372          DOI: 10.1038/bjc.1992.138

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  48 in total

1.  Hyposialylation of high-molecular-weight membrane glycoproteins parallels the loss of metastatic potential in wheat-germ agglutinin-resistant Friend leukemia cells.

Authors:  A Benedetto; G Elia; A Sala; F Belardelli
Journal:  Int J Cancer       Date:  1989-01-15       Impact factor: 7.396

2.  Involvement of soybean agglutinin binding cells in the lymphatic metastasis of the R3230AC rat mammary adenocarcinoma.

Authors:  N D Buckley; S A Carlsen
Journal:  Cancer Res       Date:  1988-03-15       Impact factor: 12.701

Review 3.  Mucins in breast cancer: recent immunological advances.

Authors:  I F McKenzie; P X Xing
Journal:  Cancer Cells       Date:  1990-03

4.  Localization and significance of peanut agglutinin-binding sites on ependymoma cells.

Authors:  J Kuratsu; N Sueyoshi; Y Mihara; Y Ushio
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

5.  Cell surface sialoprotein alterations in metastatic murine colon cancer cell lines selected in an animal model for colon cancer metastasis.

Authors:  R S Bresalier; R W Rockwell; R Dahiya; Q Y Duh; Y S Kim
Journal:  Cancer Res       Date:  1990-02-15       Impact factor: 12.701

6.  Lectin-binding characteristics of related high- and low-metastatic rat mammary adenocarcinoma cell lines.

Authors:  P Badenoch-Jones; C Claudianos; I A Ramshaw
Journal:  Invasion Metastasis       Date:  1987

7.  Cell surface glycoproteins of 13762NF mammary adenocarcinoma clones of differing metastatic potentials.

Authors:  P A Steck; G L Nicolson
Journal:  Exp Cell Res       Date:  1983-09       Impact factor: 3.905

8.  Efficient recovery of clonogenic stem cells from solid tumors and occult metastatic deposits.

Authors:  B E Miller; C J Aslakson; F R Miller
Journal:  Invasion Metastasis       Date:  1990

9.  Lymphocytic infiltration and cytotoxicity under hypoxic conditions in the EMT6 mouse mammary tumor.

Authors:  D A Loeffler; P C Keng; R B Baggs; E M Lord
Journal:  Int J Cancer       Date:  1990-03-15       Impact factor: 7.396

Review 10.  Carbohydrate antigens in human cancer.

Authors:  T Feizi
Journal:  Cancer Surv       Date:  1985
View more
  24 in total

Review 1.  Does tumour dormancy offer a therapeutic target?

Authors:  Paul E Goss; Ann F Chambers
Journal:  Nat Rev Cancer       Date:  2010-11-04       Impact factor: 60.716

2.  Neutrophils Suppress Intraluminal NK Cell-Mediated Tumor Cell Clearance and Enhance Extravasation of Disseminated Carcinoma Cells.

Authors:  Asaf Spiegel; Mary W Brooks; Samin Houshyar; Ferenc Reinhardt; Michele Ardolino; Evelyn Fessler; Michelle B Chen; Jordan A Krall; Jasmine DeCock; Ioannis K Zervantonakis; Alexandre Iannello; Yoshiko Iwamoto; Virna Cortez-Retamozo; Roger D Kamm; Mikael J Pittet; David H Raulet; Robert A Weinberg
Journal:  Cancer Discov       Date:  2016-04-12       Impact factor: 39.397

Review 3.  Noncanonical TGF-β signaling during mammary tumorigenesis.

Authors:  Jenny G Parvani; Molly A Taylor; William P Schiemann
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-03-31       Impact factor: 2.673

4.  Syndecan-Mediated Ligation of ECM Proteins Triggers Proliferative Arrest of Disseminated Tumor Cells.

Authors:  Tsukasa Shibue; Ferenc Reinhardt; Robert A Weinberg
Journal:  Cancer Res       Date:  2019-09-03       Impact factor: 12.701

5.  The outgrowth of micrometastases is enabled by the formation of filopodium-like protrusions.

Authors:  Tsukasa Shibue; Mary W Brooks; M Fatih Inan; Ferenc Reinhardt; Robert A Weinberg
Journal:  Cancer Discov       Date:  2012-05-18       Impact factor: 39.397

6.  Mammary carcinoma cell lines of high and low metastatic potential differ not in extravasation but in subsequent migration and growth.

Authors:  V L Morris; S Koop; I C MacDonald; E E Schmidt; M Grattan; D Percy; A F Chambers; A C Groom
Journal:  Clin Exp Metastasis       Date:  1994-11       Impact factor: 5.150

7.  Bispecific antibodies retarget murine T cell cytotoxicity against syngeneic breast cancer in vitro and in vivo.

Authors:  M B Moreno; J A Titus; M S Cole; J Y Tso; N Le; C H Paik; T Bakács; C M Zacharchuk; D M Segal; J R Wunderlich
Journal:  Cancer Immunol Immunother       Date:  1995-03       Impact factor: 6.968

Review 8.  Cancer progression and the invisible phase of metastatic colonization.

Authors:  Christoph A Klein
Journal:  Nat Rev Cancer       Date:  2020-10-06       Impact factor: 60.716

9.  Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs.

Authors:  Tsukasa Shibue; Robert A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-05       Impact factor: 11.205

10.  Tumor progression and metastasis in murine D2 hyperplastic alveolar nodule mammary tumor cell lines.

Authors:  V L Morris; A B Tuck; S M Wilson; D Percy; A F Chambers
Journal:  Clin Exp Metastasis       Date:  1993-01       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.